drugset / Trial / NCT01894373

Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis

NCT01894373 ↗

Phase 1/2 Completed 10 enrolled Chinese PLA General Hospital
NaSingle-groupOpen-labelTreatment

Summary

to determine the therapeutic roles of CIK cells on patients with psoriasis

Timeline

Start
2015-06
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytokine Induced Killer (CIK) cells Cell therapy — Other

Indications